ZFP30

Across TCGA pan-cancer cohorts, ZFP30 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZFP30 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZFP30 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZFP30 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, UCEC, and LUSC are the cancer types where ZFP30 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.419	0.795	<.001	30	view →
UCEC	DFS	Median	II,III,IV	0.933	0.302	.007	24	view →
LUSC	OS	Median	III,IV	0.140	0.664	.016	12	view →
SKCM	DFS	Median	III,IV	0.122	0.601	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZFP30–LUAD (OS)

Open the LUAD breakdown →